Myasthenia Gravis - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Myasthenia Gravis - Pipeline Review, H2 2018’, provides an overview of the Myasthenia Gravis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Myasthenia Gravis

- The report reviews pipeline therapeutics for Myasthenia Gravis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Myasthenia Gravis therapeutics and enlists all their major and minor projects

- The report assesses Myasthenia Gravis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Myasthenia Gravis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Myasthenia Gravis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Myasthenia Gravis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Akari Therapeutics Plc

Alexion Pharmaceuticals Inc

Alpha Cancer Technologies Inc

arGEN-X BV

BioMarin Pharmaceutical Inc

Bristol-Myers Squibb Co

CuraVac Inc

GlaxoSmithKline Plc

Grifols SA

GT ...

Akari Therapeutics Plc

Alexion Pharmaceuticals Inc

Alpha Cancer Technologies Inc

arGEN-X BV

BioMarin Pharmaceutical Inc

Bristol-Myers Squibb Co

CuraVac Inc

GlaxoSmithKline Plc

Grifols SA

GT Biopharma Inc

HanAll Biopharma Co Ltd

ImCyse SA

Millennium Pharmaceuticals Inc

Neurotune AG

Novartis AG

Pfizer Inc

Protalex Inc

Ra Pharmaceuticals Inc

Toleranzia AB

Tolerion Inc

UCB SA

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Myasthenia Gravis - Overview

Myasthenia Gravis - Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Myasthenia Gravis - Overview

Myasthenia Gravis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Myasthenia Gravis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Myasthenia Gravis - Companies Involved in Therapeutics Development

Akari Therapeutics Plc

Alexion Pharmaceuticals Inc

Alpha Cancer Technologies Inc

arGEN-X BV

BioMarin Pharmaceutical Inc

Bristol-Myers Squibb Co

CuraVac Inc

GlaxoSmithKline Plc

Grifols SA

GT Biopharma Inc

HanAll Biopharma Co Ltd

ImCyse SA

Millennium Pharmaceuticals Inc

Neurotune AG

Novartis AG

Pfizer Inc

Protalex Inc

Ra Pharmaceuticals Inc

Toleranzia AB

Tolerion Inc

UCB SA

Myasthenia Gravis - Drug Profiles

(ondansetron + pyridostigmine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

abatacept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACT-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amifampridine phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

belimumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic to Agonize Aryl Hydrocarbon Receptor for Myasthenia Gravis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bortezomib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CFZ-533 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CVMG-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

efgartigimod alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GL-2045 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HL-161 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

methotrexate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NT-1654 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRTX-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RA-101495 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ravulizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Proteins to Inhibit Complement C5 for Myasthenia Gravis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rozanolixizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide for Myasthenia Gravis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TK-21 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOL-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOL-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOL-3034 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Myasthenia Gravis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Myasthenia Gravis - Dormant Projects

Myasthenia Gravis - Discontinued Products

Myasthenia Gravis - Product Development Milestones

Featured News & Press Releases

Jun 13, 2018: Catalyst Pharmaceuticals Appoints Daniel J. Brennan as Chief Commercial Officer

Jun 12, 2018: Protalex Announces Lead Drug Candidate PRTX-100 Reduces Disease Activity in a Mouse Model of Myasthenia Gravis

Jun 06, 2018: argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis

Apr 24, 2018: argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting

Apr 23, 2018: Toleranzias CEO Charlotte Fribert on "Antigen-Specific Immune Tolerance Drug Development Summit"

Apr 19, 2018: Catalyst Pharmaceuticals Announces Enrollment of First Patient in Phase 3 Trial of Firdapse in MuSK Antibody Positive Myasthenia Gravis

Apr 09, 2018: argenx appoints Keith Woods as Chief Operating Officer

Apr 03, 2018: argenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting

Mar 26, 2018: GT Biopharma Announces Additional Positive Data From Its Phase 1 Clinical Trial For Myasthenia Gravis and Potential for Acceleration of the Start of Its Phase 2 Trial

Mar 26, 2018: argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe

Jan 09, 2018: GT Biopharma Announces Completion of Dosing in Phase I Clinical Trial of GTP-004 for Myasthenia Gravis

Jan 08, 2018: Ra Pharmaceuticals Initiates Dosing in Phase 1b Pharmacokinetic Study Evaluating RA101495 SC in Patients with Renal Impairment

Dec 21, 2017: Ra Pharmaceuticals Initiates Dosing in Phase 2 Clinical Trial Evaluating RA101495 SC in Generalized Myasthenia Gravis Patients

Dec 11, 2017: argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis

Dec 06, 2017: GT Biopharma Starts FDA Phase 1 Clinical Trial for Myasthenia Gravis Autoimmune Muscular Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Myasthenia Gravis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Myasthenia Gravis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Myasthenia Gravis - Pipeline by Akari Therapeutics Plc, H2 2018

Myasthenia Gravis - Pipeline by Alexion Pharmaceuticals Inc, H2 2018

Myasthenia Gravis - Pipeline by Alpha Cancer Technologies Inc, H2 2018

Myasthenia Gravis - Pipeline by arGEN-X BV, H2 2018

Myasthenia Gravis - Pipeline by BioMarin Pharmaceutical Inc, H2 2018

Myasthenia Gravis - Pipeline by Bristol-Myers Squibb Co, H2 2018

Myasthenia Gravis - Pipeline by CuraVac Inc, H2 2018

Myasthenia Gravis - Pipeline by GlaxoSmithKline Plc, H2 2018

Myasthenia Gravis - Pipeline by Grifols SA, H2 2018

Myasthenia Gravis - Pipeline by GT Biopharma Inc, H2 2018

Myasthenia Gravis - Pipeline by HanAll Biopharma Co Ltd, H2 2018

Myasthenia Gravis - Pipeline by ImCyse SA, H2 2018

Myasthenia Gravis - Pipeline by Millennium Pharmaceuticals Inc, H2 2018

Myasthenia Gravis - Pipeline by Neurotune AG, H2 2018

Myasthenia Gravis - Pipeline by Novartis AG, H2 2018

Myasthenia Gravis - Pipeline by Pfizer Inc, H2 2018

Myasthenia Gravis - Pipeline by Protalex Inc, H2 2018

Myasthenia Gravis - Pipeline by Ra Pharmaceuticals Inc, H2 2018

Myasthenia Gravis - Pipeline by Toleranzia AB, H2 2018

Myasthenia Gravis - Pipeline by Tolerion Inc, H2 2018

Myasthenia Gravis - Pipeline by UCB SA, H2 2018

Myasthenia Gravis - Dormant Projects, H2 2018

Myasthenia Gravis - Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Myasthenia Gravis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Figures

Number of Products under Development for Myasthenia Gravis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports